Spleen Volume as a Predictive Biomarker for Thrombocytopenia and Liver Dysfunction After Oxaliplatin-based Chemotherapy.
Spleen volume
oxaliplatin
sinusoidal obstruction syndrome
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
26
04
2020
revised:
09
05
2020
accepted:
11
05
2020
entrez:
4
6
2020
pubmed:
4
6
2020
medline:
17
7
2020
Statut:
ppublish
Résumé
We evaluated whether splenic volume (SV) predicts sinusoidal obstruction syndrome (SOS) in colorectal cancer (CRC) patients receiving capecitabine plus oxaliplatin (CapeOX) therapy. In this retrospective study, we measured SV in 41 patients receiving adjuvant CapeOX for CRC at five different time points. We compared the clinical data of the 18 patients who experienced ≥30% increases in SV immediately after vs. before CapeOX (group A) with data for the remaining 23 patients (group B). Platelet numbers decreased and the levels of hepatobiliary enzymes increased significantly 1 year after CapeOX compared with before CapeOX in group A. However, in group B, significantly decreased platelet numbers and significantly increased aspartate transaminase levels were confirmed only immediately after CapeOX, with no significant subsequent changes. SV was significantly associated with thrombocytopenia and liver dysfunction in CRC patients, and predicted SOS.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
We evaluated whether splenic volume (SV) predicts sinusoidal obstruction syndrome (SOS) in colorectal cancer (CRC) patients receiving capecitabine plus oxaliplatin (CapeOX) therapy.
PATIENTS AND METHODS
METHODS
In this retrospective study, we measured SV in 41 patients receiving adjuvant CapeOX for CRC at five different time points. We compared the clinical data of the 18 patients who experienced ≥30% increases in SV immediately after vs. before CapeOX (group A) with data for the remaining 23 patients (group B).
RESULTS
RESULTS
Platelet numbers decreased and the levels of hepatobiliary enzymes increased significantly 1 year after CapeOX compared with before CapeOX in group A. However, in group B, significantly decreased platelet numbers and significantly increased aspartate transaminase levels were confirmed only immediately after CapeOX, with no significant subsequent changes.
CONCLUSION
CONCLUSIONS
SV was significantly associated with thrombocytopenia and liver dysfunction in CRC patients, and predicted SOS.
Identifiants
pubmed: 32487632
pii: 40/6/3361
doi: 10.21873/anticanres.14319
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers
0
Oxaliplatin
04ZR38536J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3361-3370Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.